Characterization of in vivo-acquired resistance to macrolides of Mycoplasma gallisepticum strains isolated from poultry

Veterinary Research

Volumn 42, Issue 1, 2011, Pages

  Gerchman, Irena ^a   Levisohn, Sharon ^a   Mikula, Inna ^a   Manso Silván, Lucía ^b   Lysnyansky, Inna ^a  

^a KIMRON VETERINARY INSTITUTE   (Israel)

^b UMR ASTRE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

MYCOPLASMA GALLISEPTICUM;

ANTIINFECTIVE AGENT; BACTERIAL PROTEIN; DRUG DERIVATIVE; ENROFLOXACIN; QUINOLONE DERIVATIVE; RIBOSOME PROTEIN; RNA 23S; TILMICOSIN; TYLOSIN;

ANIMAL; ANIMAL DISEASE; ARTICLE; BACTERIAL GENE; BIRD DISEASE; DRUG EFFECT; GENE TARGETING; GENETICS; ISRAEL; METABOLISM; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MOLECULAR GENETICS; MOLECULAR TYPING; MULTIDRUG RESISTANCE; MYCOPLASMA GALLISEPTICUM; MYCOPLASMOSIS; PHYLOGENY; POLYMERASE CHAIN REACTION; SEASON;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FLUOROQUINOLONES; GENE TARGETING; GENES, BACTERIAL; ISRAEL; MICROBIAL SENSITIVITY TESTS; MOLECULAR SEQUENCE DATA; MOLECULAR TYPING; MYCOPLASMA GALLISEPTICUM; MYCOPLASMA INFECTIONS; PHYLOGENY; POLYMERASE CHAIN REACTION; POULTRY DISEASES; RIBOSOMAL PROTEINS; RNA, RIBOSOMAL, 23S; SEASONS; TYLOSIN;

EID: 84860592915     PISSN: 09284249     EISSN: 12979716     Source Type: Journal    
DOI: 10.1186/1297-9716-42-90     Document Type: Article

References (39)

1. Mycoplasma gallisepticum Infection. Ley DH, Yoder HW, Diseases of Poultry London: Mosby-Wolfe, Calnek BW,Barnes HJ,Beard C,McDougald LR,Saif YM, 10 1997 194 207
2. Antimicrobial drug use in poultry. Hofacre CL, Antimicrobial Therapy in Veterinary Medicine Oxford: Wiley Blackwell, Giguere S,Prescott JF,Baggot JD,Walker RD,Dowling PM, 4 2007 545 553
3. Antibiotic sensitivity patterns in field isolates of Mycoplasma gallisepticum as a guide to chemotherapy. Levisohn S, Isr J Med Sci 1981 17 661 666 7287408 (Pubitemid 11003825)
4. Epidemiology of tylosin-resistant Mycoplasma gallisepticum strains in Israel. Levisohn S, Gerchman I, American Association of Avian Pathologists 1996; Louisville, Kentucky 1996 388
5. Molecular tracking of Mycoplasma gallisepticum infection by random amplification of polymorphic DNA. Levisohn S, Gerchman I, Berkhoff JE, Ley DH, World Veterinary Poultry Association: Aug. 18-22, 1997 1997; Budapest, Hungary 1997 68
6. Macrolide resistance conferred by base substitutions in 23S rRNA. Vester B, Douthwaite S, Antimicrob Agents Chemother 2001 45 1 1 12 10.1128/AAC.45.1.1- 12.2001 11120937 (Pubitemid 32039086)
7. Comparative pharmacokinetics/pharmacodynamic modeling on three brands of 10% enrofloxacin oral formulations in broiler chickens. Gberindyer FA, Wannang N, Akiwuobu CA, Int J Poul Sci 2010 9 3 273 277
8. In vitro susceptibilities to fluoroquinolones in current and archived Mycoplasma gallisepticum and Mycoplasma synoviae isolates from meat-type turkeys. Gerchman I, Lysnyansky I, Perk S, Levisohn S, Vet Microbiol 2008 131 266 276 10.1016/j.vetmic.2008.04.006 18534788
9. Molecular characterization and determination of antimicrobial resistance of Mycoplasma gallisepticum isolated from chickens. Pakpinyo S, Sasipreeyajan J, Vet Microbiol 2007 125 59 65 10.1016/j.vetmic.2007.05.011 17570621 (Pubitemid 47454675)
10. Molecular characterization and typing of enrofloxacin-resistant clinical isolates of Mycoplasma gallisepticum. Lysnyansky I, Gerchman I, Perk S, Levisohn S, Avian Dis 2008 52 685 689 10.1637/8386-063008-RESNOTE.1 19166064
11. Use of molecular diversity of Mycoplasma gallisepticum by gene-targeted sequencing (GTS) and random amplified polymorphic DNA (RAPD) analysis for epidemiological studies. Ferguson NM, Hepp D, Sun S, Ikuta N, Levisohn S, Kleven SH, Garcia M, Microbiology 2005 151 6 1883 1893 10.1099/mic.0.27642-0 15941996 (Pubitemid 40909031)
12. Variant colony surface antigenic phenotypes within mycoplasma strain populations: Implications for species diagnosis and strain standardization. Rosengarten R, Yogev D, J Clin Microbiol 1996 34 149 158 8748292 (Pubitemid 126506912)
13. In vitro antimicrobial susceptibility Mycoplasma bovis isolated in Israel from local and imported cattle. Gerchman I, Levisohn S, Mikula I, Lysnyansky I, Vet Microbiol 2009 137 268 275 10.1016/j.vetmic.2009.01.028 19250777
14. Guidelines and recommendations for antimicrobial minimum inhibitory concentration (MIC) testing against veterinary mycoplasma species. Hannan PC, Vet Res 2000 31 4 373 395 10.1051/vetres:2000100 10958240 (Pubitemid 30621974)
15. Setting and revising antibacterial susceptibility breakpoints. Turnidge J, Paterson DL, Clin Microbiol Rev 2007 20 3 391 408 10.1128/CMR.00047-06 17630331 (Pubitemid 47175010)
16. Comparative susceptibilities of various animal-pathogenic mycoplasmas to fluoroquinolones. Hannan PCT, Windsor GD, de Jong A, Schmeer N, Stegemann H, Antimicrob Agents Chemother 1997 41 9 2037 2040 9303412 (Pubitemid 27383255)
17. In vitro and in vivo comparisons of valnemulin, tiamulin, tylosin, enrofloxacin, and lincomycin/spectinomycin against Mycoplasma gallisepticum. Jordan FTW, Forrester CA, Ripley PH, Burch DG, Avian Dis 1998 42 4 738 745 10.2307/1592709 9876842 (Pubitemid 29025821)
18. Efficacy of tilmicosin in the control of experimental Mycoplasma gallisepticum infection in chickens. Kempf I, Reeve-Johnson L, Gesbert F, Guittet M, Avian Dis 1997 41 802 807 10.2307/1592332 9454912 (Pubitemid 28091170)
19. The minimum inhibitory concentration of Tilmicosin and Tylosin for Mycoplasma gallisepticum and Mycoplasma synoviae and a comparison of their efficacy in the control of Mycoplasma gallisepticum infection in broiler chicks. Jordan FTW, Horrocks BK, Avian Dis 1996 40 326 334 10.2307/1592228 8790882
20. The complete genome sequence of the avian pathogen Mycoplasma gallisepticum strain R(low). Papazisi L, Gorton TS, Kutish G, Markham PF, Browning GF, Nguyen DK, Swartzell S, Madan A, Mahairas G, Geary SJ, Microbiology 2003 149 Pt 9 2307 2316 12949158 (Pubitemid 37160708)
21. Evaluation and comparison of various PCR methods for detection of Mycoplasma gallisepticum infection in chickens. Garcia M, Ikuta N, Levisohn S, Kleven SH, Avian Dis 2005 49 125 132 10.1637/7261-0812204R1 15839425 (Pubitemid 40383838)
22. MEGA5: Molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. Tamura K, Peterson D, Peterson N, Stecher G, Nei M, Kumar S, Mol Biol Evol 2011 2011
23. The Molecular Evolutionary Genetics Analysis (MEGA 5). http://www.megasoftware.net
24. Data analysis methods. Perrier X, Flori A, Bonnot F, Genetic diversity of cultivated tropical plants Enfield: Science Publishers, Hamon P,Seguin M,Perrier X,Glaszmann JC, 2003 43 76
25. The Dissimilarity Analysis and Representation for Windows. http://darwin.cirad.fr/darwin/
26. Performance standards for antimicrobial disk and dilution susceptibility tests for bacteria isolated from animals; Approved standard-third edition (M31-A3). Watts JL, Shryock TR, Apley M, Bade DJ, Brown SD, Gray JT, Heine H, Hunter RP, Mevius DJ, Papich MG, Silley P, Zurenko GE, CLSI 2008 28 8
27. Antimicrobial susceptibility pattern of Edwardsiella ictaluri isolates from natural outbreaks of bacillary necrosis of Pangasianodon hypophthalmus in Vietnam. Dung TT, Haesebrouck F, Tuan NA, Sorgeloos P, Baele M, Decostere A, Microb Drug Resist 2008 14 4 311 316 10.1089/mdr.2008.0848 19090723
28. Spiramycin- and tylosin-resistant strains of Mycoplasma gallisepticum isolated from breeding chickens and pipped eggs. Kuniyasu C, Yoshida Y, Takano M, Natl Inst Anim Health Q 1974 14 48 53
29. In vitro susceptibility of Mycoplasma gallisepticum field strains to tiamulin and tylosin. Hinz KH, Deutsche Tierarztliche Wochenschrift 1980 87 220 223 (in German) 6995088 (Pubitemid 10019940)
30. In vitro evaluation of various antimicrobials against Mycoplasma gallisepticum and Mycoplasma synoviae by the micro-broth method, and comparison with a commercially-prepared test system. Bradbury JM, Yavari CA, Giles CJ, Avian Pathol 1994 23 105 115 10.1080/03079459408418978 18671075
31. Induction of macrolide resistance in Mycoplasma gallisepticum in vitro and its resistance-related mutations within domain V of 23S rRNA. Wu CM, Wu H, Ning Y, Wang J, Du X, Shen J, FEMS Microbiol Lett 2005 247 2 199 205 10.1016/j.femsle.2005.05.012 15936901 (Pubitemid 40799193)
32. Mutations in 23S rRNA gene associated with decreased susceptibility to tiamulin and valnemulin in Mycoplasma gallisepticum. Li BB, Shen JZ, Cao XY, Wang Y, Dai L, Huang SY, Wu CM, FEMS Microbiol Lett 2010 308 144 149 20487023
33. Mutations in 23S rRNA account for intrinsic resistance to macrolides in Mycoplasma hominis and Mycoplasma fermentans and for acquired resistance to macrolides in M. hominis. Pereyre S, Gonzalez P, De Barbeyrac B, Darnige A, Renaudin H, Charron A, Raherison S, Bebear C, Bebear CM, Antimicrob Agents Chemother 2002 46 10 3142 3150 10.1128/AAC.46.10.3142-3150.2002 12234836
34. First report of macrolide resistant strains and description of a novel nucleotide sequence variation in the P1 adhesin gene in Mycoplasma pneumoniae clinical strains isolated in France over 12 years. Pereyre S, Charron A, Renaudin H, Bebear C, Bebear CM, J Clin Microbiol 2007 45 11 3534 3539 10.1128/JCM.01345-07 17881549 (Pubitemid 350156844)
35. Macrolides and lincomycin susceptibility of Mycoplasma hyorhinis and variable mutation of domain II and V in 23S ribosomal RNA. Kobayashi H, Nakajima H, Shimizu Y, Eguchi M, Hata E, Yamamoto K, J Vet Med Sci 2005 67 8 795 800 10.1292/jvms.67.795 16141666 (Pubitemid 41380372)
36. Emergence of macrolide-resistant Mycoplasma pneumoniae with a 23S rRNA gene mutation. Morozumi M, Hasegawa K, Kobayashi R, Inoue N, Iwata S, Kuroki H, Kawamura N, Nakayama E, Tajima T, Shimizu K, Ubukata K, Antimicrob Agents Chemother 2005 49 6 2302 2306 10.1128/AAC.49.6.2302-2306.2005 15917525 (Pubitemid 40734458)
37. Transition mutants in the 23S rRNA of erthromycin-resistant mutants of Mycoplasma pneumoniae. Lucier TS, Heitzman K, Liu S, Hu PC, Antimicrob Agents Chemother 1995 39 2770 2773 8593017
38. Characterization and molecular analysis of macrolide-resistant Mycoplasma pneumoniae clinical isolates obtained in Japan. Matsuoka M, Narita M, Okazaki N, Ohya H, Yamazaki T, Ouchi K, Suzuki I, Andoh T, Kenri T, Sasaki Y, et al. Antimicrob Agents Chemother 2004 48 12 4624 4630 10.1128/AAC.48.12.4624-4630. 2004 15561835 (Pubitemid 39577663)
39. Characterization of in vivo acquired resistance of Mycoplasma hyopneumoniae to macrolides and lincosamides. Stakenborg T, Vicca J, Butaye P, Maes D, Minion FC, Peeters J, De Kruif A, Haesebrouck F, Microb Drug Resist 2005 11 3 290 294 10.1089/mdr.2005.11.290 16201934 (Pubitemid 41434176)